{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:59:09Z","timestamp":1791316749813,"version":"4.3.1"},"reference-count":62,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T00:00:00Z","timestamp":1778198400000},"content-version":"am","delay-in-days":311,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA266172"],"award-info":[{"award-number":["R01CA266172"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R50CA211241"],"award-info":[{"award-number":["R50CA211241"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA047904"],"award-info":[{"award-number":["P30CA047904"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005496","name":"American Foundation for Pharmaceutical Education","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005496","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004897","name":"Pennsylvania Department of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["TL1TR001858"],"award-info":[{"award-number":["TL1TR001858"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.taap.2025.117375","type":"journal-article","created":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T19:15:14Z","timestamp":1746558914000},"page":"117375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Comparative in vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation"],"prefix":"10.1016","volume":"500","author":[{"given":"Joshua J.","family":"Deppas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Kiesel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lora H.","family":"Rigatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph D.","family":"Latoche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Knizner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Andy","family":"Clump","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pinakin","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank P.","family":"Vendetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Bakkenist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan H.","family":"Beumer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2025.117375_bb0005","doi-asserted-by":"crossref","first-page":"CT118","DOI":"10.1158\/1538-7445.AM2018-CT118","article-title":"Abstract CT118: PK-biomarker-safety modelling aids choice of recommended phase II dose and schedule for AZD6738 (ATR inhibitor)","volume":"78","author":"Berges","year":"2018","journal-title":"Cancer Res."},{"key":"10.1016\/j.taap.2025.117375_bb0010","doi-asserted-by":"crossref","first-page":"S842","DOI":"10.1016\/j.annonc.2022.07.780","article-title":"656MO phase I study of M6620 (VX-970, berzosertib) in combination with cisplatin and XRT in patients with locally advanced head and neck squamous cell carcinoma","volume":"33","author":"Bhatia","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0015","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.taap.2025.117375_bb0020","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMra1608986","article-title":"Recent developments in radiotherapy","volume":"377","author":"Citrin","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.taap.2025.117375_bb0025","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1200\/JCO.2014.57.5027","article-title":"Phase I dose-escalation trial of checkpoint kinase 1 inhibitor MK-8776 as monotherapy and in combination with gemcitabine in patients with advanced solid tumors","volume":"33","author":"Daud","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0030","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-019-0064-5","article-title":"Radiotherapy toxicity","volume":"5","author":"De Ruysscher","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"2","key":"10.1016\/j.taap.2025.117375_bb0035","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00280-024-04675-3","article-title":"Non-linear IV pharmacokinetics of the ATR inhibitor berzosertib (M6620) in mice","volume":"94","author":"Deppas","year":"2024","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2025.117375_bb0040","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/1535-7163.MCT-16-0239","article-title":"Radiosensitization by the ATR inhibitor AZD6738 through generation of acentric micronuclei","volume":"16","author":"Dillon","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.taap.2025.117375_bb0045","first-page":"16","volume":"12","author":"Dillon","year":"2018","journal-title":"Clin. Transl. Radiat. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0050","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/9781119500537.ch118","article-title":"Hematology of laboratory animals","author":"Enos","year":"2022","journal-title":"Schalm\u2019s Veterinary Hematol."},{"key":"10.1016\/j.taap.2025.117375_bb0055","unstructured":"E.N. Everds, 2007. Hematology of the laboratory mouse. In Fox, J.G., Davisson, M.T., Quimby, F.W., Barthold, S.W., Newcomer, C.E., Smith, A.L., The Mouse in Biomedical Research (Second Edition). Academic Press, Burlington, 133-XVIII."},{"key":"10.1016\/j.taap.2025.117375_bb0060","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2019104036","article-title":"ATR inhibition potentiates ionizing radiation-induced interferon response via cytosolic nucleic acid-sensing pathways","volume":"39","author":"Feng","year":"2020","journal-title":"EMBO J."},{"key":"10.1016\/j.taap.2025.117375_bb0065","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1634\/theoncologist.2020-0491","article-title":"A phase II single arm pilot study of the CHK1 inhibitor Prexasertib (LY2606368) in BRCA wild-type, advanced triple-negative breast Cancer","volume":"25","author":"Gatti-Mays","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.taap.2025.117375_bb0070","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1126\/science.1178331","article-title":"Development of monocytes, macrophages, and dendritic cells","volume":"327","author":"Geissmann","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.taap.2025.117375_bb0075","first-page":"6","article-title":"Spontaneously occurring cardiovascular lesions in commonly used laboratory animals","volume":"5","author":"Herman","year":"2019","journal-title":"Cardiooncology"},{"key":"10.1016\/j.taap.2025.117375_bb0080","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.1200\/jco.2011.29.15_suppl.3033","article-title":"Phase I, open-label, dose-escalation study of AZD7762 in combination with irinotecan (irino) in patients (pts) with advanced solid tumors","volume":"29","author":"Ho","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0085","doi-asserted-by":"crossref","first-page":"1764","DOI":"10.1200\/JCO.2015.64.5788","article-title":"Phase I study of LY2606368, a checkpoint kinase 1 inhibitor, in patients with advanced Cancer","volume":"34","author":"Hong","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0090","doi-asserted-by":"crossref","first-page":"3263","DOI":"10.1158\/1078-0432.CCR-17-3347","article-title":"Evaluation of Prexasertib, a checkpoint kinase 1 inhibitor, in a phase Ib study of patients with squamous cell carcinoma","volume":"24","author":"Hong","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2025.117375_bb0095","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1038\/s41392-020-0150-x","article-title":"DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer","volume":"5","author":"Huang","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.taap.2025.117375_bb0100","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41416-023-02542-1","article-title":"CHARIOT: a phase I study of berzosertib with chemoradiotherapy in oesophageal and other solid cancers using time to event continual reassessment method","volume":"130","author":"Javed","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.taap.2025.117375_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.medidd.2024.100185","article-title":"Functions and inhibitors of CHK1 in cancer therapy","volume":"22","author":"Jiang","year":"2024","journal-title":"Med. Drug Discov."},{"key":"10.1016\/j.taap.2025.117375_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232314672","article-title":"DNA damage response in Cancer therapy and resistance: challenges and opportunities","volume":"23","author":"Jurkovicova","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2025.117375_bb0115","doi-asserted-by":"crossref","first-page":"4780","DOI":"10.1158\/1078-0432.CCR-15-0479","article-title":"Molecular pathways: targeting ATR in cancer therapy","volume":"21","author":"Karnitz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2025.117375_bb0120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1007\/s00280-022-04436-0","article-title":"Dose-dependent bioavailability, absorption-rate limited elimination, and tissue distribution of the ATR inhibitor BAY-1895344 (elimusertib) in mice","volume":"89","author":"Kiesel","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2025.117375_bb0125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s00280-021-04388-x","article-title":"Dose-dependent bioavailability and tissue distribution of the ATR inhibitor AZD6738 (ceralasertib) in mice","volume":"89","author":"Kiesel","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2025.117375_bb0130","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3857\/roj.2014.32.3.103","article-title":"Mechanisms of radiation-induced normal tissue toxicity and implications for future clinical trials","volume":"32","author":"Kim","year":"2014","journal-title":"Radiat. Oncol. J."},{"key":"10.1016\/j.taap.2025.117375_bb0135","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.annonc.2021.10.009","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced\/metastatic melanoma who have failed prior anti-PD-1 therapy","volume":"33","author":"Kim","year":"2022","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0140","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10637-013-0036-7","article-title":"Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor","volume":"32","author":"King","year":"2014","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.taap.2025.117375_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00280-024-04745-6","article-title":"Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)","volume":"95","author":"Krishnamurthy","year":"2025","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2025.117375_bb0150","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005041","article-title":"Phase II study of ceralasertib (AZD6738) in combination with durvalumab in patients with advanced gastric cancer","volume":"10","author":"Kwon","year":"2022","journal-title":"J. Immunother Cancer"},{"key":"10.1016\/j.taap.2025.117375_bb0155","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/toxsci\/kft167","article-title":"Cellular impedance assays for predictive preclinical drug screening of kinase inhibitor cardiovascular toxicity","volume":"135","author":"Lamore","year":"2013","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.taap.2025.117375_bb0160","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1021\/acs.chemrestox.9b00387","article-title":"Cardiovascular toxicity induced by kinase inhibitors: mechanisms and preclinical approaches","volume":"33","author":"Lamore","year":"2020","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.taap.2025.117375_bb0165","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"Lucking","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.taap.2025.117375_bb0170","article-title":"Ceralasertib-mediated ATR inhibition combined with Olaparib in advanced cancers harboring DNA damage response and repair alterations (Olaparib combinations)","volume":"5","author":"Mahdi","year":"2021","journal-title":"JCO Precis Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0175","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13045-019-0733-6","article-title":"Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand","volume":"12","author":"Mei","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0180","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","article-title":"Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine +\/\u2212 cisplatin in patients with advanced solid tumours","volume":"125","author":"Middleton","year":"2021","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.taap.2025.117375_bb0185","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.semradonc.2006.11.009","article-title":"Normal tissue tolerance dose metrics for radiation therapy of major organs","volume":"17","author":"Milano","year":"2007","journal-title":"Semin. Radiat. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0190","doi-asserted-by":"crossref","first-page":"TPS6108","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS6108","article-title":"Phase I trial of the ATR inhibitor BAY 1895344 combined with stereotactic body radiation therapy and pembrolizumab for recurrent head and neck squamous cell carcinoma","volume":"40","author":"Mowery","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0195","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.molcel.2015.10.040","article-title":"Targeting the DNA damage response in Cancer","volume":"60","author":"O\u2019Connor","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.taap.2025.117375_bb0200","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaoncol.2021.3441","article-title":"Effect of cisplatin and gemcitabine with or without Berzosertib in patients with advanced urothelial carcinoma: a phase 2 randomized clinical trial","volume":"7","author":"Pal","year":"2021","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0205","doi-asserted-by":"crossref","first-page":"e14063","DOI":"10.1200\/JCO.2017.35.15_suppl.e14063","article-title":"Dose-exposure-response relationship between AZD6738 and peripheral monocytes","volume":"35","author":"Pierce","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0210","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.radonc.2017.09.043","article-title":"ATR\/CHK1 inhibitors and cancer therapy","volume":"126","author":"Qiu","year":"2018","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0215","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1158\/1078-0432.CCR-23-1696","article-title":"Olaparib and Ceralasertib (AZD6738) in patients with triple-negative advanced breast Cancer: results from cohort E of the plasmaMATCH trial (CRUK\/15\/010)","volume":"29","author":"Ring","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2025.117375_bb0220","series-title":"BALB\/C Mouse Hematology","author":"River","year":"2012"},{"key":"10.1016\/j.taap.2025.117375_bb0225","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.taap.2025.117375_bb0230","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/ars.2013.5668","article-title":"Ionizing radiation-induced DNA damage, response, and repair","volume":"21","author":"Santivasi","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.taap.2025.117375_bb0235","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s00280-014-2380-5","article-title":"Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors","volume":"73","author":"Sausville","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2025.117375_bb0240","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s00280-013-2234-6","article-title":"Phase I, dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumours","volume":"72","author":"Seto","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.taap.2025.117375_bb0245","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.ygyno.2021.08.024","article-title":"Combination ATR and PARP inhibitor (CAPRI): a phase 2 study of ceralasertib plus olaparib in patients with recurrent, platinum-resistant epithelial ovarian cancer","volume":"163","author":"Shah","year":"2021","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0250","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000340","article-title":"ATR inhibitor AZD6738 enhances the antitumor activity of radiotherapy and immune checkpoint inhibitors by potentiating the tumor immune microenvironment in hepatocellular carcinoma","volume":"8","author":"Sheng","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.taap.2025.117375_bb0255","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1007\/s40042-022-00574-z","article-title":"Modeling of radiation effects to immune system: a review","volume":"81","author":"Sung","year":"2022","journal-title":"J. Korean Phys. Soc."},{"key":"10.1016\/j.taap.2025.117375_bb0260","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with Topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0265","series-title":"Guidance for Industry-Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers","author":"U.S. Department of Health and Human Services Food and Drug Administration","year":"2005"},{"key":"10.1016\/j.taap.2025.117375_bb0270","first-page":"98","article-title":"Myocardial diseases of animals","volume":"124","author":"Van Vleet","year":"1986","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.taap.2025.117375_bb0275","doi-asserted-by":"crossref","first-page":"41892","DOI":"10.1038\/srep41892","article-title":"Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation","volume":"7","author":"Vendetti","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2025.117375_bb0280","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.1172\/JCI96519","article-title":"ATR kinase inhibitor AZD6738 potentiates CD8+ T cell-dependent antitumor activity following radiation","volume":"128","author":"Vendetti","year":"2018","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.taap.2025.117375_bb0285","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.bbrc.2022.01.068","article-title":"Ferroptosis plays an important role in promoting ionizing radiation-induced intestinal injuries","volume":"595","author":"Wang","year":"2022","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.taap.2025.117375_bb0290","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1158\/1535-7163.MCT-19-0019","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical Cancer models","volume":"19","author":"Wengner","year":"2020","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.taap.2025.117375_bb0295","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1158\/1078-0432.CCR-22-2444","article-title":"Combination ATR (ceralasertib) and PARP (olaparib) inhibitor (CAPRI) trial in acquired PARP inhibitor-resistant homologous recombination-deficient ovarian Cancer","volume":"29","author":"Wethington","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.taap.2025.117375_bb0300","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.radonc.2021.01.032","article-title":"A phase 1b trial of prexasertib in combination with chemoradiation in patients with locally advanced head and neck squamous cell carcinoma","volume":"157","author":"Yang","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0305","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1200\/JCO.19.02404","article-title":"Phase I trial of first-in-class ATR inhibitor M6620 (VX-970) as monotherapy or in combination with carboplatin in patients with advanced solid tumors","volume":"38","author":"Yap","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2025.117375_bb0310","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1158\/2159-8290.CD-20-0868","article-title":"First-in-human trial of the Oral Ataxia telangiectasia and RAD3-related (ATR) inhibitor BAY 1895344 in patients with advanced solid tumors","volume":"11","author":"Yap","year":"2021","journal-title":"Cancer Discov."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25001516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X25001516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T04:24:27Z","timestamp":1778473467000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X25001516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":62,"alternative-id":["S0041008X25001516"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2025.117375","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative in vivo toxicology of ATR inhibitors ceralasertib, elimusertib, and berzosertib alone and in combination with ionizing radiation","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2025.117375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117375"}}